These transfection experiments also indicated that manipulating the levels of the FX enzyme affected global cellular fucosylation and altered the interaction of colorectal cancer cells with some extracellular matrix components such as fibronectin. We also found that highly metastatic colorectal cancer variants express higher levels of FX and of sialyl Lewis-a than low metastatic variants originating in the same tumors. These results lead us to hypothesize that the FX enzyme controls the capacity of colorectal cancer to extravasate and form metastasis. If this hypothesis will be confirmed the FX enzyme could become a target molecule for metastasis prevention.
INTRODUCTION
Fucose is a component of many surface-localized and secreted molecules. It decorates the terminal portions of N-, O-, or lipid-linked glycans and modifies the core of some N-linked glycans (1) . Terminal fucosylated glycans in humans constitute several blood group antigens and function as selectin ligands (2) . Fucosylation of these ligands determines their ability to bind to the selectin family of cell adhesion molecules and therefore controls pivotal steps of selectin-dependent leukocyte and tumor cell adhesion and trafficking (1, 3, 4) . In addition to its role in adhesive reactions, fucosylation influences Notch and Cripto signaling events (5) (6) (7) (8) (9) .
The final steps of fucose biosynthesis are mediated by the GDP-Dmannose 4,6 dehydratase generating GDP-mannose-4-keto-6-Ddeoxymannose. This sugar is converted to GDP-L-fucose by the FX enzyme, functioning both as an epimerase and a reductase (10, 11) . The GDP-L fucose is then transported to the Golgi. Fucosylation of mammalian glycans is catalyzed by distinct fucosyltransferases, with catalytic activities characterized by specificity for specific glycoconjugate substrates and a requirement for GDP-fucose (12) .
The generation of FX knockout mice enabled us to conclude that fucosylation events are essential for fertility, early growth, and development, as well as for intercellular adhesion (1) . FX knockout resulted in a massive intrauterine mortality. Live-born FX-null mice exhibited a virtually complete deficiency of cellular fucosylation and a postnatal failure to thrive. FX (Ϫ/Ϫ) adults suffer from an extreme neutrophilia, myeloproliferation, and absence of leukocyte selectin ligand expression reminiscent of LAD-II/CDG-IIc (1) .
All these studies demonstrate that fucosylation plays an important role in development and in adult physiology by influencing at least two different pathways: biosynthesis of selectin ligands and signaling through the Notch and Cripto pathways.
Previous studies from our laboratory demonstrated that the FX enzyme is involved in the biosynthesis of sLe-x in activated T or B cells (13) . In head and neck squamous cell carcinomas, the FX enzyme plays a key role in the biosynthesis of selectin ligands such as sialyl Lewis-a (sLe-a) and in the interaction of these cancer cells with endothelial cells (14, 15) . In lymphocytes, as well as in head and neck squamous cell carcinomas, the FX enzyme is regulated by outside-in signaling (13, 14) .
Numerous reports indicated a correlation between a high expression of selectin ligands by epithelial cancer cells, notably colorectal cancer, and a high rate of metastasis and poor prognosis (16 -18) . The fucose-generating FX enzyme may thus be a pivotal element in cancer-associated perturbations of differentiation, survival, and proliferation, as well as in cancer cell extravasation. It is therefore important to find out if the FX enzyme is involved in controlling selectin ligand expression by colorectal cancer cells and in their interaction with endothelial selectin. The present study provides proof that this is indeed the case. 0.1 mg/mL streptomycin, and 12.5 units/mL nystatin, 5 mmol/L sodium pyruvate, nonessential amino acids, and 2-fold vitamin solution (19) . The colorectal cancer SW480 and SW620 cells were obtained from American Type Culture Collection (Manassas, VA). The SW480 cell line was derived from a primary colorectal cancer, whereas the SW620 line was derived from a lymph node metastasis of the same patient. SW480 cells were maintained in RPMI 1640 supplemented with 10% FCS. FX-cDNA SW480-transfected cells were maintained in the same medium supplemented with 800 g/mL G418 (Calbiochem, San Diego, CA). SW620 cells were maintained in Leibovitz L-15 medium supplemented with 15% FCS, 2 mmol/L L-glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin, 12.5 units/mL nystatin, 10 mmol/L HEPES buffer, and 0.075% sodium bicarbonate. The colorectal cancer HT-29 cell line was kindly provided by Dr. Livia Theodor (Gastroenterology Department, The Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel). The HT-29 cells were maintained in McCoy's modified medium (InvitrogenLife Technologies, Inc., Paisley, Scotland, United Kingdom) supplemented with 10% FCS, 2 mmol/L L-glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 12.5 units/mL nystatin. All of the cell lines were routinely cultured in humidified air with 5% CO 2 at 37°C .
Human Umbilical Vein Endothelial Cells (HUVECs). HUVECs were either purchased from Dr. Neomy Lanir (Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel) or prepared in our laboratory from umbilical cords as follows: endothelial cells were harvested by 0.25 mg/mL collagenase type II (Sigma, Holon, Israel). Cells were grown to confluence in tissue culture flasks precoated with fibronectin (20 g/mL; Biological Industries, Beit-Haemek, Israel). Cells were established as primary cultures in M199 medium supplemented with 20% FCS, 50 g/mL endothelial cell growth factor (Biomedical Technologies, Inc., Stoughton, MA), heparin (5 units/mL; Laboratoire Choay, Paris, France), and antibiotics. Cells from the third passage were taken for experiments.
Antibodies. The following antibodies were used in flow cytometry assays: anti-sialyl Lewis-a (sLe-a), anti-Lewis-a (Le-a), and anti-Lewis b (Le-b) were purchased from Seikagaku America (Falmouth, MA). Anti-sialyl Lewis-x (sLe-x) was purchased from American Type Culture Collection. Anti-Lewis-x (Le-x) and anti-CD24 were purchased from PharMingen (San Diego, CA). Anti-Lewis-y (Le-y) and anti-PSGL-1 were purchased from Serotec (Oxford, United Kingdom). Antihuman VIM2 antibodies were a kind gift from Dr. Walter Knapp (Institute of Immunology, University of Vienna, Vienna, Austria). Anti-CD62E was purchased from Southern Biotechnology Associates (Birmingham, AL). FITC-conjugated goat antimouse IgM and IgG were purchased from Jackson Immunosearch Laboratory, Inc. (West Grove, PA). The following antibodies were used in Western blotting assays: mouse monoclonal antihuman FX antibody (3G10/12) prepared in our laboratory, rabbit polyclonal antihuman FX antibody 701 (13) also prepared in our laboratory, anti-glyceraldehyde-3-phosphate dehydrogenase antibody (Chemicon International, Inc., Temecula, CA), and horseradish peroxidase-conjugated secondary goat antibody against mouse IgG (Jackson Immunosearch Laboratory, Inc.).
Plasmids. The plasmid pSUPER was kindly provided by Dr. Reuven Agami (Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands). The plasmid pRc/CMV was purchased from Invitrogen BV (Groningen, the Netherlands). The plasmid pEGFP-C was purchased from Clontech Laboratories, Inc. (Palo Alto, CA).
Construction of FX Small Interfering RNA (siRNA). FX mRNA suppression was achieved by using the pSUPER vector. Two gene-specific oligonucleotides were designed as follows: 5Ј-GATCCCCAGACGCCG-ATCTCACGGATTTCAAGAGAATCCGTGAGATCGGCGTCTTTT-TTGGAAA-3Ј and 5Ј-AGCTTTTCCAAAAAAGACGCCGATCTCA-CGGATTCTCTTGAAATCCGTGAGATCGGCGTCTGGG-3Ј. Regular characters represent regions required for the generation of the siRNA as previously described (20) , and bold characters represent FX-specific complementary sequences. Both oligonucleotides were denatured at 95°C for 4 minutes, annealed at 70°C for 10 minutes, and cooled down slowly. Oligonucleotides were then phosphorylated by the use of T4 polynucleotide kinase at 37°C for 30 minutes. This oligonucleotide mixture was ligated into the pSU-PER vector predigested with BglII and HindIII and pretreated with calf intestinal phosphatase. A mutated FX siRNA that served as control was generated by introducing a point mutation (G to C) at position 24 in the first FX-specific complementary sequence oligonucleotide shown above. This oligonucleotide was cloned to the pSUPER vector along with the second FXspecific complementary oligonucleotide shown above.
Flow Cytometry. Cells (5 ϫ 10 5 ) were incubated for 45 minutes at 4°C with primary antibodies directed against the tested selectin ligand. After a wash with cell sorter medium (RPMI 1640 supplemented with 5% FCS and 0.01% sodium azide), the cells were incubated for 45 minutes at 4°C with FITCconjugated goat antimouse IgG or IgM. After an additional wash, antigen expression on 5000 live cells was determined using a Becton Dickinson FACSort (Mountain View, CA) and CellQuest software. Baseline staining was obtained by adding cell sorter medium to the cells instead of primary antibody. Flow cytometry scores for selectin ligand expression were calculated as described previously (13) . The scores represent the multiplication of the mean fluorescence by the percent positive cells ϫ10 -4 . Scores for each selectin ligand were divided into three categories: high, medium, and low. For sLe-a, high ϭ 8.2 to 19.7, medium ϭ 5.7 to 7.6, and low ϭ 1.8 to 0.2; for Le-b, high ϭ 8.7 to 11.6, medium ϭ 2.2 to 5.6, and low ϭ 0.1 to 1.3; for sLe-x, high ϭ 7 and medium ϭ 2.3 to 4.9.
RNA Preparation and Northern Blot Analysis. Total RNA was prepared, and Northern blotting was performed as described by Eshel et al. (14) in our lab.
Western Blotting. Colorectal cancer cells were lysed with Laemmli sample buffer (21) . Lysates were boiled for 10 minutes, centrifuged, and applied on a miniprotean II system (Bio-Rad, Hercules, CA) for SDS-PAGE using a 12% slab gel as described by Laemmli (21) . Electrophoretic transfer of proteins from the polyacrylamide gel to nitrocellulose (Schleicher & Schull, Dassel, Germany) was performed by a mini-transblot electrophoretic cell (Bio-Rad) at 250mA for 2 hours. After transfer, the nitrocellulose membrane was incubated at room temperature with 3% BSA in TBS-Tween for 30 minutes to block free binding sites on the membrane. The blocked nitrocellulose membrane was incubated over night with anti-FX 3G10/12 monoclonal antibody, diluted 1:16 in 1% BSA in TBS-Tween with 0.02% sodium azide or with rabbit polyclonal antihuman FX antibody 701(2), diluted 1:1000 in 5% milk in TBS-Tween with 0.02% sodium azide, then washed three times for 5 minutes with TBS-Tween and incubated for 50 minutes with horseradish peroxidase-conjugated secondary goat antibody against mouse or rabbit IgG diluted 1:10,000 with 5% milk in TBS-Tween at room temperature. Finally, the nitrocellulose membrane was washed five times for 5 minutes with TBSTween. The bands were visualized by chemiluminescence-enhanced chemiluminescence reaction (Amersham, Buckinghamshire, United Kingdom) and autoradiography by exposure to Kodak XAR5 film (Eastman Kodak Co., Rochester, NY) for 1 to 5 minutes.
The quantification of protein in the lanes was determined in reference to the amount of glyceraldehyde-3-phosphate dehydrogenase in the lanes. This was performed by incubating the membrane with anti-glyceraldehyde-3-phosphate dehydrogenase diluted 1:1000 with 5% milk in TBS-Tween with 0.02% sodium azide.
Lectin Blot. The first steps of blotting were performed as described above for Western blotting. After transfer of the proteins to nitrocellulose, the membrane was incubated at room temperature for 60 minutes with 3% BSA in PBS-0.05% Tween-20 to block free binding sites on the membrane. The blocked nitrocellulose membrane was incubated for 2 hours with horseradish peroxidase-conjugated Ulex europaeus agglutinin lectin (Sigma), which binds to L-fucose (22) , diluted 1:2000 in PBS containing 3% BSA and 0.1% Tween-20, then washed four times for 10 minutes with PBS containing 0.1% Tween-20. The bands were visualized by the chemiluminescence-enhanced chemiluminescence reaction (Amersham) and autoradiographed by exposure to Kodak X-AR5 film (Eastman Kodak Co.) for 5 seconds.
Transfection. SW620 cells were transfected with pSUPER-FX siRNA (205 cells) or with pSUPER-FX-mutated siRNA oligonucleotides (360 control cells) by electroporation using the Electro cell manipulator 830 (BTXGenetronics, San Diego, CA). Thirty micrograms of pSUPER and 3 g of the pBabe-puro plasmid were used for transfection. Forty-eight hours after electroporation, the cells were selected with 1 g/mL puromycin. Individual clones were then picked, expanded and analyzed for FX protein levels. To increase transfection yield, cells were re-transfected using the pSUPER coupled with pcDNA3.1-zeo vectors. In this case, 500 g/mL zeocin was used as a selection marker. The transfected cells were grown in the presence of 25 mmol/L fucose. SW480 cells were cotransfected either with FX-cDNA pRc/CMV vector or with pRc/CMV vector without insert together with pEGFP-C vector by electroporation.
Adhesion of Colorectal Cancer to HUVECs. Ninety-six-well culture plates were coated with 50 L of 20 g/mL fibronectin per well for 30 minutes at 37°C. After one wash with PBS, 3 ϫ 10 4 HUVECs in a volume of 100 L/well were cultured on the plate for 16 hours to form a confluent monolayer. Endothelial cells were stimulated for 4 hours with human recombinant IFN-␥ (100 units/mL) and recombinant tumor necrosis factor ␣ (100 units/mL) and washed. A total of 2 ϫ 10 6 colorectal cancer cells were washed twice with PBS and suspended in 1 mL of cold PBS, labeled with the CFDA-SE reagent (250 nmol/L; Molecular Probes, Eugene, OR) for 5 minutes, and then washed with 2 mL of FCS. After an additional wash with PBS, the labeled cells (1 ϫ 10 5 / 100 L) were added to a stimulated HUVEC monolayer in TBS containing 2 mmol/L CaCl 2 (for selectin-depended adhesion) and incubated for 30 minutes at 37°C. The total fluorescence signal was that of labeled cells added to the well before removing the nonadherent cells, which were removed by three washes with PBS. Total fluorescence and that of adhering cells was measured by a fluorescent ELISA reader (Bio-Tek FL500; Bio-Tek Instruments, Inc., Winooski, VT) at wavelength of 490/530. The results are presented as percent adhesion. The number of adherent green fluorescent protein (GFP)-transfected cells was determined by counting fluorescent cells in several fields with the aid of a fluorescence microscope (magnification ϫ100, FITC filter, Olympus IX70; Olympus, Hamburg, Germany).
Adhesion of Colorectal Cancer to rE-Selectin, Extracellular Matrix (ECM), or Fibronectin. Nontissue culture plates (Nunc-Immuno plate NUNC; Nunc International, Roskilde, Denmark) were coated for 60 minutes at room temp with 100 L/well of 2 g/mL recombinant E-selectin (R&D Systems, Minneapolis, MN) diluted in TBS-Tween containing 2 mmol/L CaCl 2 . Three wells were not coated for detection of nonspecific binding. Supernatants were aspirated from the wells, and 200 L of blocking medium (1% BSA in TBS-Tween containing 2 mmol/L CaCl 2 ) were added for at least 30 minutes at room temperature. Cells were labeled with CFDA-SE reagent as described above. Labeled cells (1 ϫ 10 5 /100 L) suspended in 1% BSA in TBS-Tween, 2 mmol/L CaCl 2 were added to rE-selectin or uncoated wells for 45 minutes at 37°C. The rest of the assay was performed as described above. A similar procedure was performed with plates coated with a mixture of matrix proteins (E-TCMT-F NOVAmed; Jerusalem, Israel) or with fibronectin in the presence of 5 mmol/L MgCl 2 .
Statistical Analysis. Significance was calculated using the two-way Student's t test. Table 1 shows the expression profile of several fucosylated glycans by 12 colorectal cancer cell lines. This profile was derived from several repetitions of flow cytometry experiments. All lines expressed sLe-a as well as Le-b. High levels of sLe-a were expressed by four cell lines and medium levels by four lines. Four cell lines expressed low levels of sLe-a. High levels of Le-b were expressed by cells of two lines (427 and 1203, which also expressed high levels of sLe-a). Four lines expressed medium levels of Le-b, and six lines expressed low levels of this fucosylated glycan. In all, it seems that the expression pattern of sLe-a by the various cell lines was similar to that of Le-b and to some extent to Le-a. The expression levels of sLe-x, a dominant selectin ligand on activated lymphocytes, were rather low. With the exception of four cell lines, of which, one expressed high and three medium levels of sLe-x, all other lines expressed either low levels of this selectin ligand or did not express it at all.
RESULTS

An Expression Profile of Fucosylated Glycans by Colorectal Cancer Cell Lines
Taken together, these results indicated that sLe-a is the dominant selectin ligand in all cell lines tested. Because of its relative high expression by most of the colorectal cancer cell lines assayed, we consider sLe-a to be the representative selectin ligand of colorectal cancer cells.
In view of the possibility that in colorectal cancer, as in HNSCC (14) , the fucose-generating FX enzyme functions as a limiting factor in sLe-a biosynthesis, we studied, in the following series of experiments, its contribution to sLe-a expression. Fig. 1 shows a regression curve correlating the expression of FX protein to that of sLe-a in several colorectal cancer cell lines. A significant correlation between these two parameters was seen. A similar correlation between FX expression levels and other selectin ligands was not found (results not shown).
Expression Levels of the FX Enzyme Correlate with Those of sLe-a
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Metastatic Colorectal Cancer Cell Line Variants Express Higher Levels of the FX Enzyme and of sLe-a Than the Corresponding Nonmetastatic Variants
To assess the contribution of the FX enzyme to various malignancy associated characteristics, we compared cell lines having an identical genetic background but that differ in their metastatic phenotype. High and low metastatic variants originating from two patients were used. SW480 and SW620 cells originated in one patient, and KM12C, KM12SM, and KM12L4 originated from another patient.
SW480 and SW620 are colorectal cancer cell lines derived, correspondingly, from the primary tumor and from a lymph node metastasis of a single patient. This cell pair was recently validated as an appropriate model to study differences between primary and secondary tumors (23) . Fig. 2A demonstrates that the metastatic SW620 cells express higher levels of the FX enzyme than the nonmetastatic SW480 cells. These cells also express higher levels of sLe-a (Fig. 2B) .
The KM12C cell line was established from a primary colorectal cancer, and the KM12SM and KM12L4 lines are metastatic variants of KM12C derived from nude mouse xenotransplants. These three cell lines thus have the same genetic background (19) . The KM12SM cells are more metastatic than the KM12L4 cells (19) . Fig. 3A demonstrates that the metastatic KM12SM variant expresses higher levels of the FX enzyme than the primary KM12C cells. The more metastatic KM12SM variant expresses twice as much FX enzyme than the less metastatic KM12L4 variant in which FX expression was only marginally higher than that by the primary KM12C cells. Fig. 3B shows that the expression of sLe-a in the three cell lines correlated with the FX expression by these cells. The results presented above established, thus, a correlation between the metastatic phenotype of colorectal cancer and expression levels of the FX enzyme and of sLe-a. Fig. 4A demonstrates that the metastatic SW620 cells expressing higher levels of FX and sLe-a than SW480 cells (Fig. 2) , adhere better to activated HUVEC (P Ͻ 0.03).
The Adhesive Capacity of Colorectal Cancer Cells to Activated Endothelial Cells and to E-Selectin Is Linked to the Expression Levels of Endogenous FX and sLe-a
To test whether the differential adhesion of SW620 and SW480 cells to activated HUVECs reflects their adhesion capacity to Eselectin, we measured the adhesion of these cells to recombinant E-selectin. The results presented in Fig. 4B show that the metastatic SW620 cells adhere significantly better to rE-selectin than SW480 cells (P Ͻ 0.02), suggesting that the adhesion of the cells is mediated by a selectin-selectin ligand interaction.
Similar results were obtained when comparing the adhesive capacity of primary KM12C cells with that of the metastatic KM12SM cell variant. The highly metastatic KM12SM cells, expressing high levels of the FX enzyme and of sLe-a (Fig. 3) , adhered better to activated HUVECs (P Ͻ 0.03; Fig. 5A ) and to rE-selectin (P Ͻ 0.02; Fig. 5B ) than the KM12C cells, which express a low metastatic behavior and low levels of FX and sLe-a.
The FX Enzyme Directly Regulates the Expression of sLe-a and the Selectin-Mediated Adhesion of Colorectal Cancer Cells
FX cDNA Transfection. The results presented in the previous sections show a positive correlation between expression levels of the fucose-generating FX enzyme, expression levels of the selectin ligand sLe-a, and adhesion of colorectal cancer cells to activated HUVECs and rE-selectin. The next set of experiments was aimed to determine if the FX enzyme directly regulates the expression of sLe-a on colorectal cancer cells and their adhesion to activated HUVECs and rE-selectin. It was assumed that if fucose is indeed a limiting factor in selectin ligand biosynthesis in colorectal cancer cells and thus of their E-selectin-dependent adhesion to activated HUVECs, then overexpressing the FX enzyme in low FX-expressing cells would result in higher levels of selectin ligand expression and in an up-regulated adhesive capacity of FX cDNA-transfected cells. By the same token, down-regulating the levels of FX by siRNA should decrease the expression levels of selectin ligands. The FX siRNA-transfected cells should, as a result, express a down-regulated adhesive capacity. The experiments described below demonstrate that this is indeed the case.
We first overexpressed the FX enzyme in SW480 cells, which express very low levels of endogenous FX and sLe-a (Fig. 2) . These cells were transiently cotransfected with FX and GFP cDNA (in a 10:1 ratio). These cells expressed higher levels of FX protein than control cells transfected with GFP alone (Fig. 6A) . Fig. 6B shows that these transfectants adhered better to activated HUVECs than cells transfected with GFP cDNA alone (P Ͻ 0.001) and shows that the adhesion of the FX-transfectants was reduced to background levels (i.e., adhesion to nonactivated HUVECs) by antibodies directed against E-selectin (P Ͻ 0.001).
Adhesion experiments in which rE-selectin was used instead of activated HUVECs (Fig. 6C ) yielded similar results (P Ͻ 0.001).
Antibodies against E-selectin reduced the adhesion of the FXtransfectants to rE-selectin also in this case (P Ͻ 0.001). (Fig. 7A) . The FX siRNA-transfected 205 cells expressed also lower levels of the FX protein than the control transfected 360 cells (Fig. 7B) . It is interesting to note that the down-regulation of FX protein was more remarkable at the protein level than at the mRNA level. No explanation for this observation is available at this stage. Fig. 7C demonstrates that the siRNA-transfected 205 cells express less sLe-a than control transfectants. Fig. 8 shows that the FX siRNA-transfected 205 cells adhered less well to rE-selectin than control 360 cells (P Ͻ 0.01). In conformity with the results reported in Fig. 6C , antibodies directed against E- selectin blocked to background levels the adhesion of the control 360 cells to rE-selectin (P Ͻ 0.001; Fig. 8) . The low adhesion of the FX siRNA-transfected 205 cells to rE-selectin was also blocked to background levels by these antibodies (P Ͻ 0.001; Fig. 8 ). An isotype control antibody used in these experiments had no blocking activity whatsoever.
The transfection experiments described above provide conclusive evidence that a FX3selectin ligand3adhesion pathway operates in colorectal cancer. However, the involvement of other fucosylated adhesion molecules controlled by the fucose-generating FX enzyme in the adhesion of colorectal cancer cannot be ruled out.
The siRNA transfectants adhered less well also to ECM (P Ͻ 0.002; Fig. 9A ). To identify the ECM protein to which adhesion was reduced by down-regulating the fucose-generating FX enzyme, we compared the adhesion of FX siRNA transfectants (205 cells) and of control transfectants (360 cells) to collagen, laminin, and fibronectin. Whereas the adhesion of both types of transfectants to collagen and laminin was similar, the FX siRNA-transfected cells adhered significantly less well to fibronectin than the controls (P Ͻ 0.04; Fig. 9B ). This finding led us to tentatively conclude that cellular adhesion to fibronectin may be fucose dependent.
We also tested if knocking down FX levels by FX siRNA transfection would affect adhesion to uncoated tissue-culture plastic vessels under normal culture conditions. Three independent experiments showed a reduced survival of SW620 cells in which levels of FX were knocked down by FX siRNA transfection, as compared with control cells transfected with mutated FX siRNA. At the time point of 96 hours after the initiation of culture, the average number of viableadherent control cells was 1.96-fold higher than that of the FX siRNA transfectants (P Ͻ 0.02).
The above results suggest that FX knockdown may influence global fucosylation of colorectal cancer glycomolecules. To test this possibility, we evaluated levels of fucoconjugates in FX siRNA transfectants (205 cells) and in control 360 cells. Fig. 10 shows a lectin blot Lysates were subjected to Western blot analysis as described in the legend for Fig. 2A . B, adhesion to HUVECs and its blocking by antibodies against E-selectin. The transfected cells were incubated on activated HUVECs, as described in the legend for Fig. 4A . The bars represent mean Ϯ SD of values obtained from five independent experiments. P Ͻ 0.001 for the difference between FX cDNA and control transfectants. Similar experiments were performed in the presence of antibodies against E-selectin. Two independent experiments were performed. P Ͻ 0.001 for the difference between the adhesion of FX cDNA transfectants in the presence or absence of the antibody. C, adhesion to rE-selectin and its blocking by antibodies against E-selectin. The transfected cells were incubated on rE-selectin-coated plates, as described in the legend for Fig. 4B . The bars represent mean Ϯ SD of values obtained by counting several fields in two independent experiments. Adhesion was blocked, in two independent experiments, by anti-E-selectin antibodies (␣ E-selectin; P Ͻ 0.001). The adhesion presented in B and C was determined by counting adherent, GFP-expressing cells under a fluorescence microscope (the average number of cells per field was obtained by counting several fields). Control ϭ SW480 cells cotransfected with control pRc/CMV vector and GFP; FX cDNA ϭ SW480 cells cotransfected with FX cDNA and GFP; see Materials and Methods. of extracts derived from control or FX siRNA-transfected cells developed with the Ulex europaeus agglutinin 1 agglutinin, a fucosespecific lectin (22) . A clear reduction in global fucosylation is indicated in the FX siRNA transfectants.
DISCUSSION
The attachment of selectin ligand-expressing tumor cells to selectin-expressing endothelial cells is crucial event in the initial step of tumor cell-endothelium interactions, including extravasation (24 -29) . Therefore, understanding the regulation of selectin ligand synthesis in tumor cells is crucial for the development of metastasis-targeting manipulations.
The proper functioning of selectin ligands requires their fucosylation (1, 30 -34) , mainly by the fucose-generating FX enzyme (1, 13, 14, 33, 34) . The present study documents a functional relationship between expression levels of the FX enzyme and those of the selectin ligand sLe-a by colorectal cancer cells. This conclusion was based on a direct and positive correlation between expression levels of FX and those of sLe-a by several colorectal cancer cell lines. Furthermore down-regulating FX expression by FX siRNA transfection decreased sLe-a expression.
We also documented a functional axis linking FX and sLe-a expression to the capacity of colorectal cancer cells to adhere to Eselectin. It was thus found that the FX enzyme is a limiting factor for the capacity of at least those colorectal cancer cells used in this study to adhere to endothelium. This conclusion is supported both by correlative evidence, as well as by direct evidence provided by transfection experiments.
It is assumed that highly metastatic tumor variants extravasate more efficiently than cells with a low metastatic phenotype (18, 26, 29) . This implies that the former variants would adhere better to endothelial cells than the latter ones. Indeed, the highly metastatic variants SW620 (23) and KM12SM (19) adhered better to endothelial cells than the corresponding low metastatic variants SW480 and KM12C. Each of these variant pairs originated from a single patient. The highly metastatic variants expressed also higher levels of the FX enzyme and of sLe-a than the variants expressing a low metastatic phenotype. It was interesting to note that KM12SM, the most highly metastatic variant of the KM12C primary tumor (19) , expressed higher levels of the FX enzyme and of sLe-a than KM12L4, the less metastatic variant from the same tumor. It seems, therefore, that the degree of malignancy correlates positively with expression of the fucose-generating FX enzyme and of its selectin ligand product sLea.
Taken together, these results lead us to hypothesize that the FX enzyme controls, by regulating selectin ligand biosynthesis, the interaction of at least certain colorectal cancer cells with endothelium and thus the capacity to extravasate and form metastasis. If this hypothesis will be confirmed by testing additional high and low metastatic cell pairs, the FX enzyme could become a target molecule for prevention of metastasis.
It was also demonstrated that the FX siRNA-mediated decrease of FX expression by colorectal cancer cells down-regulated the ability of the siRNA-transfected cells to bind to the ECM protein fibronectin. This raises the possibility that fucose is also involved in the interac- tion between tumor cells and ECM. Indeed it was demonstrated that fucosylation of integrins, e.g., ␣ 3 ␤ 1 , is essential for a correct assembly of the integrin ␣ and ␤ subunits and for the binding to fibronectin (35) .
Fucose participates not only in controlling adhesive properties but also in other functions such as modifying signal transduction events. For example, Fringe, a fucose-specific glycosyltransferase initiates elongation of O-linked fucose residues attached to epidermal growth factor-like sequence repeats of Notch (6) . This glycosylation modulates Notch-mediating signaling (5) . Another example is the O-fucose modification of Cripto. This modification is essential for Nodaldependent signaling (7). Because both Notch as well as Nodal-mediated signaling bear importance with respect to tumor progression (9, 36 -39) , it would be of interest to compare these signaling pathways in colorectal cancer variants expressing high or low levels of FX.
Taken together, the results of the present study, as well as those of other studies cited above, suggest that altering expression levels of the FX enzyme, thereby altering global fucosylation of colorectal cancer cells, could have far reaching effects on the survival and phenotype of these cells.
The FX enzyme supplies ϳ90% of the cellular fucose while the rest is supplied by the salvage pathway (1, 40) . In this pathway, extracellular fucose is taken up by the cell, phosphorylated by a fucose-kinase, and subsequently converted to GDP L-fucose by GDP-fucose-pyrophosphorylase. The GDP L-fucose generated by the salvage pathway undergoes an identical biosynthetic route as the GDP L-fucose generated by the FX enzyme (34, 40) . To fully assess the role of the FX enzyme in regulating various fucose-dependent reactions in colorectal cancer cells such as adhesion, Notch, or Cripto-mediated signaling, it would be important to determine the relative contribution of the salvage pathway to the cellular fucose supply.
NF-B in Squamous Cell Carcinoma
In the article on NF-B in squamous cell carcinoma in the September 15, 2004 issue of Cancer Research (1), the entries in Tables 1  and 2 
